skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Scaffolded HIV-1 vaccine immunogens

Abstract

The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.

Inventors:
;
Issue Date:
Research Org.:
SLAC National Accelerator Lab., Menlo Park, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1735281
Patent Number(s):
10780178
Application Number:
16/177,165
Assignee:
The Scripps Research Institute (La Jolla, CA)
Patent Classifications (CPCs):
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
DOE Contract Number:  
AC02-76SF00515
Resource Type:
Patent
Resource Relation:
Patent File Date: 10/31/2018
Country of Publication:
United States
Language:
English

Citation Formats

Zhu, Jiang, and He, Linling. Scaffolded HIV-1 vaccine immunogens. United States: N. p., 2020. Web.
Zhu, Jiang, & He, Linling. Scaffolded HIV-1 vaccine immunogens. United States.
Zhu, Jiang, and He, Linling. Tue . "Scaffolded HIV-1 vaccine immunogens". United States. https://www.osti.gov/servlets/purl/1735281.
@article{osti_1735281,
title = {Scaffolded HIV-1 vaccine immunogens},
author = {Zhu, Jiang and He, Linling},
abstractNote = {The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2020},
month = {9}
}

Patent:

Save / Share:

Works referenced in this record:

Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1
journal, September 2002


Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles
journal, June 2016


Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env
journal, March 2015


Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers
journal, December 2015


Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability
journal, June 2016


Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design
journal, April 2015


Design of a hyperstable 60-subunit protein icosahedron
journal, June 2016


Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
journal, February 2014


Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
journal, March 2013


Alteration of immune response using pan DR-binding peptides
patent, April 1998


The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years
journal, September 2005


Toward an AIDS Vaccine
journal, May 2008


Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity
journal, September 2015